Navigation Links
New Assay Detects 100 Percent of Stage I, II and III Colon Cancers in Pre-Clinical Trials

KNOXVILLE, Tenn., Sept. 16 /PRNewswire/ -- Marking a major milestone in the early detection and management of colon cancer, EDP Biotech Corporation (EDP), a developer of immunodiagnostic tests for humans and animals, announced today that its ColoMarker(TM) assay achieved 100 percent detection rate for colon cancers presented at stages I through III in pre-clinical trials. ColoMarker is the first assay of its kind to enable both early detection screening and patient management capabilities, presenting the potential to save time, money and, most importantly, lives.

"ColoMarker could radically change the way we detect and treat colon cancer," said Kevin Jones, Ph.D., Chief Scientific Officer of EDP. "In fact, 30 percent of colon cancer deaths annually are avoidable by early screening. ColoMarker can help save lives through early detection and effective treatment. It will also help reduce healthcare costs by eliminating unnecessary colonoscopies and other procedures."

Colon cancer is the second most prevalent cancer in the U.S., surpassed only by lung cancer. In 2009, nearly 150,000 new colon cancer cases will be confirmed and more than 55,000 people are projected to die from the disease.

ColoMarker could make accurate, early detection of colon cancer as easy as an additional blood test conducted as a routine part of patients' annual physicals, in much the same way Prostate-Specific Antigen (PSA) tests are used to screen for prostate cancer today. The assay would become the first to combine diagnostic applications with use as a patient management tool that could help physicians determine the effectiveness of colon cancer treatment in patients.

ColoMarker's Preliminary Potential

The pre-clinical trials, conducted from January through August 2009, evaluated 2,370 freshly drawn serum samples. ColoMarker, which uses a proprietary biomarker developed by EDP, had an overall accuracy rate of 93 percent.

When compared to the Fecal Occult Blood (FOB) test, the current clinical standard test recommended for colon cancer screening, ColoMarker performed extremely well, according to Jones. In a test panel of 243 samples drawn from patients who exhibited possible colon cancer and were referred to a specialist, the false positive rate was significantly lower for the ColoMarker assay (11 percent) than for the FOB assay (30 percent). Notably, the ColoMarker assay detected 100 percent of early-stage (Stage I) colon cancer; the FOB assay missed about 60 percent.*

"The FOB test is not 'patient friendly,' meaning that most people either refuse to use the test or cannot collect the sample effectively," continued Jones. "ColoMarker is the first 'blood-based' assay that will simplify the whole process for both patients and doctors."

The ColoMarker assay currently tests a serum sample on a microtiter plate ELISA platform.

EDP has applied for patents on the reagents and assay, and is moving toward next steps for the commercialization of the test.

About EDP Biotech

EDP Biotech Corporation is a privately held medical device company focused on the development and sale of immunodiagnostic tests for both humans and animals. EDP utilizes more than 30 years of research and development in identification and purification of proteins present in the early stages of biological changes for production of in vitro diagnostic tests whose primary target is early detection.

*The reported results for the FOB test were lower than seen in other studies. The patients used for the study may have caused this. The false positive rate on FOB for patients referred to a GI specialist is higher than seen for the general population. Even for this problematical patient set, the ColoMarker assay provided significantly better performance.

ColoMarker(TM) is a trademark of the EDP Biotech Corporation.

SOURCE EDP Biotech Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Bio/Data Corporation Launches vW Select(TM) - The Worlds First and Only Complete Ristocetin CoFactor Assay
2. Genomic Health Reports Favorable Commentary on Value of Multigene Assays From the St. Gallen Expert Consensus Meeting on the Primary Treatment of Early Breast Cancer
3. O2h and Hypoxium Announce an Agreement to Offer Hypoxiums Specialised In Vitro, Cell-Based Oncology Assays via O2hs Biology Affiliate Program
4. Frost & Sullivan Recognizes Cisbio Bioassays for Technology Innovation
5. Abbott & BioGenex Extend the Technology Co-development and Distribution Agreement for Marketing the Xmatrx(R) Advanced Staining Platform for the Automation of FISH, IHC and ISH Molecular Diagnostic Assays
6. Assay Designs(TM), Inc. Announces Release of First Available Product for Multiplex Analysis of Heat Shock Proteins
7. ForteBio Launches New Assay Capabilities for High-Sensitivity Protein Quantitation and Fragment Screening on Its Octet(R) Platform
8. AutoGenomics New RVP Assay Addresses Current Challenge to Detect Flu A - Swine H1N1
9. BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management
10. Genomic Health Announces Positive Preliminary Results from QUASAR Validation Study of Oncotype DX(R) Colon Cancer Assay
11. Polycystic Kidney Disease Assay at Cornell University Uses Transgenomics Surveyor Nuclease & WAVE Technology
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... Clinovo recently appointed Jeff Parr and Ed Donaldson ... clinical data solutions business. , Jeff Parr has spent the past decade providing quality ... Dennison, Thermo Fisher, and Ab Sciex to name a few. He is based ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... educational opportunities for school age children in the areas of Science, Technology, Engineering ... sectors of the national economy, and the program aims to increase the number ...
(Date:10/12/2015)... ... October 12, 2015 , ... Spirax Sarco, the leader in products and services ... 600 compact clean steam generator . This unit is a skid mounted system ... HTM2010, and EN285 standards. The CMS-C 600 generator can produce up to a ...
(Date:10/12/2015)... , Oct. 12, 2015  Rebiotix Inc. today ... has designated its lead Microbiota Restoration Therapy (MRT) ... of recurrent Clostridium difficile (C diff) ... that causes 29,000 deaths in the U.S. annually. ... company that was founded to revolutionize the treatment ...
Breaking Biology Technology:
(Date:10/9/2015)... ) ... "Samsung Galaxy S6 Fingerprint Sensor - Reverse ... --> ) has announced ... S6 Fingerprint Sensor - Reverse Costing Analysis" ... Research and Markets ( ) ...
(Date:10/8/2015)... 8, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... smart wallet announces that revenues for the three ... compared with $113,00 for the three months ended ... ended September 30, 2015 were approximately $520,000. ...
(Date:10/6/2015)... CITY , Oct. 6, 2015 Track ... announced today that it has signed a contract with ... services across the full range of sentences under the ... President of the Americas. "This contract with the Virginia ... of the US and advances our position as a ...
Breaking Biology News(10 mins):